A groundbreaking stem cell transplant procedure has kept two patients with a severe autoimmune disease in remission for more than 15 years without requiring ongoing medication. The findings, reported by researchers from IRCCS San Raffaele Scientific Institute in Italy, offer hope for people with treatment-resistant autoimmune conditions that don't respond to standard therapies.

What Is Neuromyelitis Optica and Why Is It So Difficult to Treat?

Neuromyelitis optica (NMO) is a rare but aggressive autoimmune disease in which the body's immune system mistakenly attacks astrocytes, which are support cells in the brain and spinal cord. Without treatment, NMO can lead to serious disability. The disease is driven by rogue antibodies called AQP4-IgG that destroy these critical support cells.

Current therapies exist to manage NMO, but they come with significant limitations. These treatments are expensive, not always effective, and carry their own risks. Relapses are common, meaning patients often need to stay on medication indefinitely to prevent disease flare-ups. This is why researchers have been exploring more radical approaches to achieve lasting disease control.

How Does Immune System Replacement Work?

The treatment used in this case is called allogeneic hematopoietic cell transplantation (alloHCT). Rather than trying to suppress the immune system with drugs, this approach essentially reboots it entirely using donor stem cells from another person. Here's how the process works:

• Immune System Clearing: Before the transplant, patients receive chemotherapy drugs called fludarabine and treosulfan to eliminate their existing B cells, which are the immune cells that produce the harmful AQP4-IgG antibodies.
• Stem Cell Infusion: Healthy donor stem cells are then introduced into the bloodstream, where they multiply and rebuild the body's immune defenses from scratch without the disease-causing antibodies.
• Immune Reprogramming: The new immune system develops without the faulty instructions that caused it to attack the body's own cells.

What Happened to the Two Patients?

Both patients were 28 years old when they underwent the alloHCT procedure. The results have been remarkable. Over follow-up periods of 15 and 16 years, both patients remained completely relapse-free without any ongoing immunosuppressive medication. The disease-driving antibodies permanently disappeared from their bodies.

The male patient experienced particularly dramatic improvements. He regained neurological function and has since fathered two children. According to the researchers, he has "resumed a normal life." The female patient, while experiencing less dramatic neurological recovery, achieved a good quality of life and regained some use of her arms. Neither patient required further medication to maintain their remission.

"Over more than 15 years of follow-up, both patients remained relapse-free without ongoing immunosuppression, accompanied by enhanced quality of life and the disease-driving antibodies permanently disappearing," stated the researchers from IRCCS San Raffaele Scientific Institute.

Researchers, IRCCS San Raffaele Scientific Institute

Why Is This Finding So Significant?

This case represents the longest follow-up of alloHCT patients with NMO reported to date. While alloHCT has been used to treat other conditions like cancer and sickle-cell disease, it has only been tried a small number of times for NMO. The extended follow-up period is crucial because it demonstrates that the benefits are not temporary but can last for decades.

The researchers emphasized that no currently approved therapy allows patients to remain treatment-free while maintaining sustained disease control and complete disappearance of pathogenic antibodies. This makes the findings particularly noteworthy for patients who have exhausted other treatment options.

What Are the Risks and Limitations?

It's important to note that alloHCT is a drastic procedure with significant risks. The process of shutting down and rebuilding the immune system can lead to serious complications. In this study, the male patient developed a chronic immune deficiency that required ongoing antibody supplementation and experienced swollen lymph nodes that eventually resolved on their own. The female patient developed bladder cancer, which was surgically treated.

The researchers were careful to note that neither complication was proven to be directly caused by the transplant, and the male patient's immune deficiency remains unexplained. Because of these risks, the researchers recommend that alloHCT be reserved for carefully selected younger patients who have failed standard therapies and have aggressive, treatment-resistant disease.

"In this evolving therapeutic landscape, alloHCT should be considered within a balanced, individualized risk-benefit framework. Its use is best reserved for carefully selected younger patients who are intolerant to standard therapies and present with aggressive, treatment-refractory disease or concomitant autoimmune conditions," the researchers noted.

Researchers, IRCCS San Raffaele Scientific Institute

What Does This Mean for Future Autoimmune Treatments?

The findings suggest that immune system replacement may achieve long-term disease control and possibly even a cure in selected cases, though larger studies are needed to confirm safety and identify the best candidates for treatment. The researchers emphasized that we're now seeing a variety of immune system reset treatments emerge, backed by science, using either donor cells or cells from patients themselves.

As improvements are developed for how these treatments are administered and as risks are minimized, immune system replacement represents a promising route forward for people with severe autoimmune diseases that don't respond to conventional therapies. The 15-year remission achieved by these two patients offers hope that such dramatic, long-lasting improvements may be possible for others facing similar treatment-resistant conditions.